Anti-TNF therapies, such as infliximab (IFX) and adalimumab (ADA), are effective treatments for patients with multiple systemic inflammatory disorders, such as inflammatory bowel disease, autoimmune arthropathies, and sarcoidosis, as they inhibit the pro-inflammatory cytokine TNF-α, reducing inflammation and promoting remission. Here, TNF is linked to inflammatory bowel disease.